{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:23:09Z","timestamp":1774527789428,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,6,30]],"date-time":"2005-06-30T00:00:00Z","timestamp":1120089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:p><jats:bold>Abstract: Background: <\/jats:bold> Autoimmune hepatitis (AIH) is a chronic liver disease that is effectively treated with immunosuppressive therapy. Predniso(lo)ne, often in combination with azathioprine, is the basic therapeutic option to induce remission. However, this regimen can cause numerous side effects. The aim of the present study was to evaluate budesonide as a treatment option in the induction of remission in patients with previously untreated AIH.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Between October 1998 and August 1999, 12 patients were treated with 3\u2003mg budesonide thrice daily for 3 months in this open one\u2010arm multicenter phase IIa study. Primary end point was induction of remission indicated by a drop of aspartate aminotransferase and alanine aminotransferase levels below two times the upper limit of normal.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Seven of the 12 patients (58%) reached complete remission, three patients (25%) had a partial response. Thus, 10\/12 individuals (83.3%) responded to therapy. Therapy was tolerated well in 10\/12 cases (83.3%).<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> Budesonide monotherapy was effective in the induction of remission and well tolerated in treatment na\u00efve patients with AIH. It should be further evaluated in prospective controlled trials and should be compared to predniso(lo)ne both in monotherapy and in combination with azathioprine.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2005.01122.x","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T08:00:44Z","timestamp":1126598444000},"page":"927-934","source":"Crossref","is-referenced-by-count":79,"title":["Budesonide in previously untreated autoimmune hepatitis"],"prefix":"10.1111","volume":"25","author":[{"given":"Johannes","family":"Wiegand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Sch\u00fcler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kanzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Kreisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Koletzko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L. M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut W.","family":"M\u00f6llmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pr\u00f6ls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,14]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"701","article-title":"Susceptibility to autoimmune chronic active hepatitis","volume":"13","author":"Donaldson P T","year":"1991","journal-title":"human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90157-8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90427-8"},{"key":"e_1_2_6_5_2","first-page":"541","article-title":"Autoimmune hepatitis in childhood","volume":"25","author":"Gregorio G V","year":"1997","journal-title":"a 20-year experience"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040436"},{"key":"e_1_2_6_7_2","first-page":"998","article-title":"Meeting report","volume":"18","author":"Johnson P J","year":"1993","journal-title":"International Autoimmune Hepatitis Group"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.21.1.78"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.qjmed.a067264"},{"key":"e_1_2_6_10_2","first-page":"820","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease","volume":"63","author":"Soloway R D","year":"1972","journal-title":"a controlled study of treatments and early prognosis"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)33990-3"},{"key":"e_1_2_6_12_2","first-page":"687","article-title":"Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy","volume":"80","author":"Czaja A J","year":"1981","journal-title":"correlation of serum transaminase and gamma globulin levels with histologic features"},{"key":"e_1_2_6_13_2","first-page":"1502","article-title":"Autoimmune hepatitis","volume":"120","author":"Manns M P","year":"2001","journal-title":"clinical challenges"},{"key":"e_1_2_6_14_2","first-page":"876","article-title":"Prednisone for chronic active liver disease","volume":"16","author":"Summerskill W H","year":"1975","journal-title":"dose titration, standard dose, and combination with azathioprine compared"},{"key":"e_1_2_6_15_2","first-page":"487","volume-title":"Inflammatory Bowel Disease: From Bench to Bedside","author":"Andus T T S.","year":"1994"},{"key":"e_1_2_6_16_2","volume-title":"Glukokortikoidtherapie chronisch entz\u00fcndlicher Darmerkrankungen. Von den Grundlagen zur rationalen Therapie","author":"May B","year":"1996"},{"key":"e_1_2_6_17_2","first-page":"42","volume-title":"Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease \u2013 From Basic Principles to Rational Therapy","author":"M\u00f6llmann H W","year":"1996"},{"key":"e_1_2_6_18_2","first-page":"107","volume-title":"Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease \u2013 From Basic Principles to Rational Therapy","author":"M\u00f6llmann H W","year":"1996"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198428060-00001"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311303"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311304"},{"issue":"3","key":"e_1_2_6_22_2","first-page":"98","article-title":"Review article","volume":"11","author":"Hamedani R","year":"1997","journal-title":"drug development in inflammatory bowel disease: budesonide\u2013a model of targeted therapy"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001080050127"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70254-9"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00334.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(95)95672-7"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.0010000001"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-35704"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.204"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840040409"},{"key":"e_1_2_6_31_2","unstructured":"M\u00f6llmannH W Sch\u00fclerA B\u00f6kerK H W HochhausG MannsM P.Pharmacokinetics of budesonide in patients with autoimmune hepatitis. Falk Symposium 114 Basler Liver Week 1999."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50266"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2005.01122.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2005.01122.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:29:50Z","timestamp":1695889790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2005.01122.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,14]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1478-3231.2005.01122.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01122.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,14]]}}}